AMR: Snipr Biome Aps raises €43m to programme pathogens for deathCopenhagen-based SNIPR BIOME Aps raised €43m in a series A financing led by seed investor Lundbeckfonden Emerge (Copenhagen) and LSP and co-financed by North-East Family Office (Copenhagen) … more ➔
Small-molecule acts as broad-band influenza entry blockerResearchers at Janssen Pharmaceutical Companies of Johnson & Johnson in Leiden have developed a small molecule antibody mimic, that prevents entry of multiple influenza virus serotypes. more ➔
Seventure starts second microbiome-focussed fundSeventure Partners has announced the first close of its second microbiome fund designed to put €200m in 20 companies developing microbiome-based health solutions. more ➔
Numab AG bags CHF70m in licencing dealSwiss immunology and immuno-oncology specialist Numab Innovation AG has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics Inc. more ➔
Biogen bags UK company Nightstar for US$877mBiogen has strengthened its portfolio with Nightstar Therapeutics, a British gene therapy specialist for rare inherited eye disorders. more ➔
EMA approves eight meds for marketThe EMA’s human medicines committee (CHMP) has recommended eight medicines for approval in its last meeting in London, two thereof orphan medicines. Three got conditional marketing authori … more ➔
Genfit set to raise $100m in Nasdaq IPOFrench Genfit SA has registered at SEC for an Nasdaq IPO of ADS in conjunction with private placements in Europe and the US. more ➔
Targeting NFkappaB protects tendons from injuryResearchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation. more ➔
Anaveon bags CHF35m series A financingUniversity Zurich spin-off Anaveon AG announced it will proceeds from its financing round to push development of its preclinical IL-2-receptor agonist. more ➔
AMR network CARB-X expands reachThe global antibacterial innovation network CARB-X has expanded its reach by adding six new life-science organisations to its fight against antimicrobial resistance (AMR). more ➔
